Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125584
Filing Date
2024-11-12
Accepted
2024-11-12 16:45:34
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tern-20240930.htm   iXBRL 10-Q 1861807
2 EX-10.1 tern-ex10_1.htm EX-10.1 60589
3 EX-10.2 tern-ex10_2.htm EX-10.2 66532
4 EX-10.3 tern-ex10_3.htm EX-10.3 7975
5 EX-31.1 tern-ex31_1.htm EX-31.1 16638
6 EX-31.2 tern-ex31_2.htm EX-31.2 16635
7 EX-32.1 tern-ex32_1.htm EX-32.1 9160
8 EX-32.2 tern-ex32_2.htm EX-32.2 9160
  Complete submission text file 0000950170-24-125584.txt   8573085

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tern-20240930.xsd EX-101.SCH 1334981
61 EXTRACTED XBRL INSTANCE DOCUMENT tern-20240930_htm.xml XML 1550654
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39926 | Film No.: 241449263
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)